フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
An all-new interview with Scott Sand, CEO of Ingen Technologies, Inc. is also available on WallSt.net NEW YORK, Feb. 12 /PRNewswire/ -- The...
NEW YORK, Jan. 18 /PRNewswire/ -- The Analyst's Review is a daily podcast hosted by WallSt.net editor, Henry Truc that airs every morning at 9...
ADDITIONAL RESOURCES: Video, hard copy requests, contact information and more available at: http://www.prnewswire.com/broadcast/23534/consumer.html...
SOUTH SAN FRANCISCO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Genentech, Inc. today announced that it received a Complete Response Letter from...
SOUTH SAN FRANCISCO, Calif., Aug. 17 /PRNewswire-FirstCall/ -- The Genentech Foundation for Biomedical Sciences announced today that its Board...
CHICAGO, Dec. 7 /PRNewswire/ -- Seven Summits Research issues the following Morning Update at 8:30 AM EST with new PriceWatch Alerts for key...
Tiki Barber, Shaun Alexander and Others Join Merril Hoge and Dedicate 2005 Season to Raising Awareness of One of the Fastest Growing Cancers in...
Genentech Foundation for Biomedical Sciences Bolsters Innovation in Health Science Education With $1.2 Million for Bay Area Programs SOUTH SAN...
Preliminary Phase IIb Study Showed Rituxan Improved Symptoms in Rheumatoid Arthritis Patients Who Failed One or More Disease-Modifying Anti-Rheumat...
Addendum to Genentech Announces Fourth Quarter and Full Year 2004 Results (FINANCIAL TABLES) SOUTH SAN FRANCISCO, Calif., Jan. 10...
/FIRST AND FINAL ADD - SFW058 - GENENTECH ANNOUNCES THIRD QUARTER 2004 RESULTS/ GENENTECH, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS...
Genentech Receives Subpoena on Rituxan(R) SOUTH SAN FRANCISCO, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Genentech, Inc., has received a subpoena...
Genentech Foundation for Biomedical Sciences Awards More Than $1 Million to Science Education Programs in The Bay Area SOUTH SAN FRANCISCO...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約